Polygenic risk scores predict the progression from unipolar depression to bipolar or psychiatric disorders.
Compared with usual treatment, the use of long-acting injectable antipsychotics significantly increased the time to first hospitalization in patients with early-phase schizophrenia.
Dexmedetomidine is currently available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting.
Adverse events, including voluntary psychiatric admission, suicide attempt, serious violent incident, voluntary admission to a general medical ward, overdose of medication or painkillers, were highest among the combined group compared to the monotherapies.
Predictors of suicide death include male sex, later age at first diagnosis, prior mood disorder diagnosis
The researchers concluded that the correlation between interregional cortical thinning during maturation and expression patterns of genes associated with multiple psychiatric disorders suggested a common molecular process.
Maladaptive cognitive emotion regulation and global emotion dysregulation emerged as mediators of the effects of trauma on depressive and positive symptoms in early nonaffective psychosis.
Acadia Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for pimavanserin (Nuplazid®) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Data from animal models and postmortem tissue analysis indicate that interneuron dysfunction is an essential feature of schizophrenia.
Minerva Neurosciences announced that its phase 3 trial of roluperidone (MIN-101) did not meet the primary and key secondary end points for the treatment of negative symptoms in schizophrenia.